Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for SNN and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for SNN and 80,000+ other tickers.
See exactly how SNN's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for SNN and 80,000+ other tickers.
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The…
SNN launches the LYNX COBLATION Laryngeal Wand, combining precise dissection, rapid debulking and hemostasis for airway procedures.
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, today announces the publication by expert clinicians of new consensus-based guidance - developed by them for the use of single-use negative pressure wound therapy (sNPWT) in closed surgical incisions. The guidance is supported by practical clinical practice recommendations for Germany and has been published in the internationally recognised journal of surgery Die Chirurgie. The new German consensus was supported by Smith+Nephew, a pioneer in sNPWT and manufacturer of the PICO™7 sNPWT system.
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, today announces the publication of new consensus-based guidance - developed independently by expert clinicians for the use of single-use negative pressure wound therapy (sNPWT) in closed surgical incisions. The guidance is supported by practical clinical practice recommendations for Germany. Published in internationally recognised journal of surgery Die Chirurgie, the new German consensus was supported by Smith+Nephew, a pioneer in sNPWT and manufacturer of the PICO™7 sNPWT system.
Smith & Nephew continues to demonstrate solid business recovery, with robust revenue, profit, and free cash flow growth across all divisions. SNN's 2026 outlook targets 6% underlying revenue growth, 8% organic trading profit growth, and $800 million in free cash flow, with a new $500 million share buyback announced. Completion of the 12-point plan delivered mixed results: revenue growth targets were met, but trading margin fell short, prompting a new 'RISE' strategy with 2028 financial targets.
Smith & Nephew plc (SNN) Shareholder/Analyst Call Transcript